DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 204384/S-006

SUPPLEMENT APPROVAL

Janssen Research & Development, LLC
Attention: Michele Dias, MS
Manager, Global Regulatory Affairs
920 Route 202 South
Raritan, NJ 08869

Dear Ms. Dias:

Please refer to your Supplemental New Drug Application (sNDA) dated July 06, 2015, received July 06, 2015, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for SIRTURO (bedaquiline) 100 mg Tablet.

This Prior Approval supplemental application provides for the following:

- Revisions to the **DOSAGE AND ADMINISTRATION** section, Recommended Dosage in Combination Therapy subsection (2.3) and **ADVERSE REACTIONS** section, Clinical Studies Experience subsection (6.1) regarding the need to refer to the package insert of the drugs to be used in combination with SIRTURO.

- Revisions to the **CLINICAL PHARMACOLOGY** section, Microbiology subsection (12.4) to include results of the bedaquiline phenotypic drug susceptibility testing and quality control ranges and information about mechanism of resistance.

In addition, the package insert and the Medication Guide were revised to add the manufacturing site, (b) (4) for the drug substance bedaquiline fumarate and the REFERENCES section (15) was updated.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA

automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Fariba Izadi, Pharm.D., Regulatory Health Project Manager at (301) 796-0563.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research.,

Content of Labeling
MedGuide

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
12/09/2015